<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171009036672N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-24</date_registration>
      <primary_sponsor>Vice President of Research and Technology Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Moisturizing effect of 12% ammonium lactate lotion in the treatment of dry skin in dialysis patients</public_title>
      <acronym></acronym>
      <scientific_title>Formulation and Evaluation of the Moisturizing Effect of Ammonium Lactate 12% Lotion on Dermatological Disease of the Uremic Patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-03-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>25</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63159</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: A double-blind randomized comparative clinical trial was conducted to investigate the effectiveness of ammonium lactate 12% against placebo lotion without medicinal substance. A study in the form of a questionnaire design related to the complications of uremic itching and the effect of 12% ammonium lactate lotion, which was provided to the participants and was filled again four weeks later by them to compare the effect of the lotion.

The randomization method was done in a simple way and randomly in two groups.
The randomization unit was checked individually in two different groups.
The randomization tool was filled in the form of a hand skin evaluation questionnaire (expression of uremic itching side effects) before and after using the drug and for four weeks. Finally, using statistical software, the percentage of patients' satisfaction with the drug was evaluated.
The way of constructing the random sequence was that the patients were randomly selected in two different groups
  Concealment was done in such a way that the patients did not know about the use of drugs or placebos, and drug distribution was done by the researcher . In this way, the first group used the drug (ammonium lactate 12%) and the second group used a placebo, i.e. a 50% w/w paraffin emulsion in water, Blinding description: The method of blinding was done in such a way that the participants, the ward nurse and the clinical supervisor were not aware of the drug or placebo, and the drug distribution was done by the researcher. Also, the person evaluating the outcome and the person analyzing the data did not know how to distribute the drug and placebo among the patients. In this way, the first group of participants used the drug (ammonium lactate 12%) in one day without knowing the name, and the second group used a placebo, i.e. 50% w/w paraffin emulsion in water.
Patients were randomly selected according to uremic pruritus problems: the first group used medicine and the second group used placebo
In this double-blind study, patients in both groups are evaluated before treatment and one month after using a hand skin stereomicroscope with 3x magnification in terms of visual scoring to determine the level of skin moisture and overall skin damage. This system has 6 grades, from 6 (normal skin without crusting and skin irritation) to 0 (skin cracks and wide fissures, redness or occasional bleeding) by the researcher and the ward nurse.</study_design>
      <phase>2</phase>
      <hc_freetext>Severe dry skin.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The effectiveness of ammonium lactate 12% was investigated. A study in the form of a questionnaire design related to the complications of uremic itching and the effect of the drug, which was given to the participants and filled again four weeks later by them to compare the effect of the lotion. Intervention 2: control group: Placebo, lotion, placebo without medicinal substance, a study in the form of a questionnaire design related to the effects of uremic itching and the effect of the placebo, which was given to the participants and filled again four weeks later by them to compare the effect of the lotion.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
How to improve patients can be presented in the form of a table

When:
Access period starts from the summer of 1401 for 6 months

To whom:
Researchers working in academic and scientific institutions

Conditions:
Available for medical purposes and through a doctor

Where to obtain:
emails

How to obtain:
The data will be emailed to them within a week

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>atoosa haghighizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>pharmacy school, ferdowsi university of mashhad, park sq., montazer blv.</address>
        <city>mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9188617871</zip>
        <telephone>+98 51 3180 1126</telephone>
        <email>atoosa.hz@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>omid rajabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>pharmacy school, ferdowsi university of mashhad, park sq., montazeri blv.</address>
        <city>mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9188617871</zip>
        <telephone>+98 51 3180 1126</telephone>
        <email>rajabio@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Uric patient treated with peritoneal dialysis
Existence of dry skin</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of sensitivity to any of the components of the product
Reluctance to participate or continue the plan
Existence of skin diseases except dryness</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The effectiveness of ammonium lactate 12% was investigated. A study in the form of a questionnaire design related to the complications of uremic itching and the effect of the drug, which was given to the participants and filled again four weeks later by them to compare the effect of the lotion.</i_keyword>
      <i_keyword>control group: Placebo, lotion, placebo without medicinal substance, a study in the form of a questionnaire design related to the effects of uremic itching and the effect of the placebo, which was given to the participants and filled again four weeks later by them to compare the effect of the lotion.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Determining skin moisture. Timepoint: Before starting treatment and 3 days after taking the drug for a month. Method of measurement: The system has 6 degrees, from a score of 6 normal skin without scales  ﴾to 0 degrees﴿ skin cracks.</prim_outcome>
      <prim_outcome>General skin damage. Timepoint: Before starting treatment and 3 days after taking the drug for a month. Method of measurement: The system has 6 degrees, from a score of 6 normal skin without scales  ﴾to 0 degrees﴿  extensive fissures redness or occasional bleeding.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice President of Research and Technology Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-05-19</approval_date>
        <contact_name>Ethics Committee in Mashhad university of Medical Sciences Research</contact_name>
        <contact_address>Research and Technology Vice-Chancellor, next to Hoize Cinema, Qurashi Building,  Mashhad, University St. mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
